Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ionis Pharmaceuticals, Inc. (NASDAQ: IONS).

Full DD Report for IONS

You must become a subscriber to view this report.


Recent News from (NASDAQ: IONS)

FDA accepts Novartis' marketing application for SMA Type 1 gene therapy AVXS-101
The FDA accepts under Priority Review Novartis' (NYSE: NVS ) marketing application seeking approval for gene therapy AVXS-101 for the treatment of spinal muscular atrophy (SMA) Type 1. The agency's action date is in May 2019. More news on: Novartis AG, Biogen Inc., Ionis Pharmaceuticals,...
Source: SeekingAlpha
Date: December, 03 2018 07:32
A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed
There’s not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ ...
Source: SeekingAlpha
Date: November, 20 2018 05:21
Does Achaogen Have The Operational Runway Required To Deliver Value?
Achaogen is not on the verge of bankruptcy We all know that the endless siren calls around Achaogen's ( AKAO ) relatively precarious financial position have been a major contributing factor to the stock's decline since the approval of Zemdri for cUTI, but not for BSI caused by CRE in the ...
Source: SeekingAlpha
Date: November, 07 2018 09:10
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Stifel 2018 Healthcare Conference on Wednesday, Nove...
Source: PR Newswire
Date: November, 07 2018 07:00
Ionis Pharmaceuticals, Inc. (IONS) CEO Stan Crooke on Q3 2018 Results - Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call November 06, 2018 11:30 AM ET Executives Wade Walke - Investor Relations Stan Crooke - Chairman of the Board & Chief Executive Officer Beth Hougen - Chief Financial Officer Brett Monia - Chief Operating Off...
Source: SeekingAlpha
Date: November, 06 2018 23:18
Ionis Pharmaceuticals beats by $0.13, misses on revenue
Ionis Pharmaceuticals (NASDAQ: IONS ): Q3 GAAP EPS of -$0.03 beats by $0.13 . More news on: Ionis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 07:06
Ionis Reports Third Quarter 2018 Financial Results
CARLSBAD, Calif. , Nov. 6, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the third quarter of 2018 and highlighted its recent business and pipeline successes. "We enter the fourth quarter in a position of financial stren...
Source: PR Newswire
Date: November, 06 2018 07:00
Notable earnings before Tuesday's open
AAC , ABC , ADM , AES , AFI , ANIP , APD , AVNS , BCC , BCPC , BDX , BHC , BIOS , BLD , BR , CORE , CTLT , CVS , ELAN , EMES , EMR , ETM , EXPD , FI , FRTA , FSS , GCP , GLDD , GLT , GOGO , GTN , GTX , HAE , HPT , HSIC , IONS , IRWD , JELD , JLL , KEYW...
Source: SeekingAlpha
Date: November, 05 2018 17:30
Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting
CARLSBAD, Calif. , Oct. 31, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that Ionis and its collaborators will present data from its neurological disease programs at the Society for Neuroscience (SfN) Annual Me...
Source: PR Newswire
Date: October, 31 2018 07:00
ProQR in-licenses Worldwide rights to ophthalmology drug candidate from Ionis Pharmaceuticals
ProQR Therapeutics N.V. (NASDAQ: PRQR ) signs an agreement with Ionis Pharmaceuticals (NASDAQ: IONS ) to license QR-1123 (formerly “IONIS-RHO-2.5 Rx ”), an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin  ...
Source: SeekingAlpha
Date: October, 29 2018 08:58

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1445.3645.0946.1044.73964,826
2018-02-2651.1851.3751.58950.39537,835
2018-02-2350.2251.0351.0549.41547,991
2018-02-2250.3349.8851.3649.84789,210
2018-02-2150.1049.8651.5949.45611,948

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12169,664286,19659.2824Short
2018-12-11112,919152,36974.1089Short
2018-12-1091,344144,92463.0289Short
2018-12-07213,076301,51770.6680Short
2018-12-06228,502316,89872.1059Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IONS.


About Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

Logo for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

Not available

 

Contact Information

 

 

Current Management

  • Stanley T. Crooke / CEO
  • Daniel L. Kisner / President, COO
  • B. Lynne Parshall / CFO, Secretary

Current Share Structure

  • Market Cap: $5,501,558,255 - 05/17/2018
  • Issue and Outstanding: 125,520,380 - 04/30/2018

 


Recent Filings from (NASDAQ: IONS)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: August, 31 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: August, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 27 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: August, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 07 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: July, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 20 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: June, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 31 2018

 

 


Daily Technical Chart for (NASDAQ: IONS)

Daily Technical Chart for (NASDAQ: IONS)


Stay tuned for daily updates and more on (NASDAQ: IONS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IONS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IONS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IONS and does not buy, sell, or trade any shares of IONS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/